on Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences' Abstract Accepted for Presentation at SITC 2024
Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company, announced that its abstract has been selected for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas. The conference will take place from November 6-10, 2024, with both in-person and virtual attendance options available.
The presentation, titled "DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint Blockade in Models of MSS/MMRp CRC," will be delivered by Dr. Reid Bissonnette. It will be held on November 8, 2024, from 9:00 a.m. to 7:00 p.m. CST at the George R. Brown Convention Center.
Xenetic focuses on innovative immuno-oncology technologies, utilizing its DNase platform to improve cancer treatment outcomes by targeting neutrophil extracellular traps. Their current efforts are directed towards advancing their systemic DNase program as an adjunctive therapy for challenging oncology indications.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xenetic Biosciences, Inc. news